HK1209741A1 - Tricyclic compounds for inhibiting the cftr channel - Google Patents
Tricyclic compounds for inhibiting the cftr channel Download PDFInfo
- Publication number
- HK1209741A1 HK1209741A1 HK15110599.7A HK15110599A HK1209741A1 HK 1209741 A1 HK1209741 A1 HK 1209741A1 HK 15110599 A HK15110599 A HK 15110599A HK 1209741 A1 HK1209741 A1 HK 1209741A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibiting
- tricyclic compounds
- cftr channel
- present
- cftr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739335P | 2012-12-19 | 2012-12-19 | |
| US61/739,335 | 2012-12-19 | ||
| US201361906141P | 2013-11-19 | 2013-11-19 | |
| US61/906,141 | 2013-11-19 | ||
| PCT/IB2013/061043 WO2014097148A1 (en) | 2012-12-19 | 2013-12-17 | Tricyclic compounds for inhibiting the cftr channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1209741A1 true HK1209741A1 (en) | 2016-04-08 |
Family
ID=50030372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15110599.7A HK1209741A1 (en) | 2012-12-19 | 2013-12-17 | Tricyclic compounds for inhibiting the cftr channel |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20140171417A1 (https=) |
| EP (1) | EP2935278B1 (https=) |
| JP (1) | JP6284546B2 (https=) |
| KR (1) | KR20150097660A (https=) |
| CN (1) | CN105143230B (https=) |
| AP (1) | AP2015008539A0 (https=) |
| AR (1) | AR094122A1 (https=) |
| AU (1) | AU2013365739A1 (https=) |
| BR (1) | BR112015014292A2 (https=) |
| CA (1) | CA2895660A1 (https=) |
| CL (1) | CL2015001730A1 (https=) |
| CR (1) | CR20150325A (https=) |
| CU (1) | CU20150066A7 (https=) |
| EA (1) | EA201591177A1 (https=) |
| ES (1) | ES2628369T3 (https=) |
| HK (1) | HK1209741A1 (https=) |
| IL (1) | IL239389A0 (https=) |
| MX (1) | MX2015007939A (https=) |
| PE (1) | PE20151055A1 (https=) |
| PH (1) | PH12015501386A1 (https=) |
| SG (1) | SG11201504594QA (https=) |
| TN (1) | TN2015000279A1 (https=) |
| TW (1) | TW201429974A (https=) |
| UY (1) | UY35211A (https=) |
| WO (1) | WO2014097148A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| AU2013365827A1 (en) | 2012-12-19 | 2015-07-09 | Novartis Ag | Tricyclic compounds as CFTR inhibitors |
| EA201591177A1 (ru) | 2012-12-19 | 2015-11-30 | Новартис Аг | Трициклические соединения для ингибирования канала cftr |
| TWI686429B (zh) | 2014-09-19 | 2020-03-01 | 美商摩曼帝夫特性材料公司 | 用於經控制之矽氧烷交聯的鉑(ii)二烯錯合物 |
| HUE054399T2 (hu) * | 2015-04-23 | 2021-09-28 | Trevi Therapeutics Inc | Vegyületek viszketéses állapotok kezelésére |
| CN106478558B (zh) * | 2016-10-17 | 2019-03-29 | 天津雅奥科技发展有限公司 | 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法 |
| US12319686B2 (en) | 2019-01-17 | 2025-06-03 | Hoffmann-La Roche Inc. | Process for the preparation of tetrahydropyridopyrimidines |
| BR112021025048A2 (pt) * | 2019-06-12 | 2022-02-01 | Univ California | Métodos de tratamento de diarreia por ácido biliar |
| EP4329815A1 (en) | 2021-04-29 | 2024-03-06 | Novartis AG | Deubiquitinase-targeting chimeras and related methods |
| CN117654560B (zh) * | 2023-12-01 | 2024-06-04 | 安徽泽升科技股份有限公司 | 一种通过氧化氨基连续化制备硝基化合物的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1207161B1 (en) | 1999-08-25 | 2006-01-18 | Banyu Pharmaceutical Co., Ltd. | Novel isoindole derivatives |
| JP2002255967A (ja) | 2001-02-27 | 2002-09-11 | Banyu Pharmaceut Co Ltd | イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2007332754A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
| WO2009042270A2 (en) * | 2007-07-05 | 2009-04-02 | Trustees Of Boston University | Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| WO2012166658A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| AU2013365827A1 (en) | 2012-12-19 | 2015-07-09 | Novartis Ag | Tricyclic compounds as CFTR inhibitors |
| EA201591177A1 (ru) | 2012-12-19 | 2015-11-30 | Новартис Аг | Трициклические соединения для ингибирования канала cftr |
-
2013
- 2013-12-17 EA EA201591177A patent/EA201591177A1/ru unknown
- 2013-12-17 HK HK15110599.7A patent/HK1209741A1/xx unknown
- 2013-12-17 CA CA2895660A patent/CA2895660A1/en not_active Abandoned
- 2013-12-17 KR KR1020157019061A patent/KR20150097660A/ko not_active Withdrawn
- 2013-12-17 PE PE2015001056A patent/PE20151055A1/es not_active Application Discontinuation
- 2013-12-17 CN CN201380073218.3A patent/CN105143230B/zh not_active Expired - Fee Related
- 2013-12-17 WO PCT/IB2013/061043 patent/WO2014097148A1/en not_active Ceased
- 2013-12-17 SG SG11201504594QA patent/SG11201504594QA/en unknown
- 2013-12-17 JP JP2015548837A patent/JP6284546B2/ja not_active Expired - Fee Related
- 2013-12-17 AU AU2013365739A patent/AU2013365739A1/en not_active Abandoned
- 2013-12-17 AP AP2015008539A patent/AP2015008539A0/xx unknown
- 2013-12-17 EP EP13826625.9A patent/EP2935278B1/en active Active
- 2013-12-17 US US14/109,922 patent/US20140171417A1/en not_active Abandoned
- 2013-12-17 BR BR112015014292A patent/BR112015014292A2/pt not_active IP Right Cessation
- 2013-12-17 MX MX2015007939A patent/MX2015007939A/es unknown
- 2013-12-17 US US14/653,084 patent/US9359381B2/en active Active
- 2013-12-17 ES ES13826625.9T patent/ES2628369T3/es active Active
- 2013-12-18 TW TW102147023A patent/TW201429974A/zh unknown
- 2013-12-19 UY UY0001035211A patent/UY35211A/es not_active Application Discontinuation
- 2013-12-19 AR ARP130104861A patent/AR094122A1/es unknown
-
2015
- 2015-06-11 IL IL239389A patent/IL239389A0/en unknown
- 2015-06-16 TN TNP2015000279A patent/TN2015000279A1/fr unknown
- 2015-06-17 PH PH12015501386A patent/PH12015501386A1/en unknown
- 2015-06-18 CL CL2015001730A patent/CL2015001730A1/es unknown
- 2015-06-19 CU CUP2015000066A patent/CU20150066A7/es unknown
- 2015-06-19 CR CR20150325A patent/CR20150325A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150325A (es) | 2015-08-10 |
| JP2016509579A (ja) | 2016-03-31 |
| WO2014097148A9 (en) | 2015-02-19 |
| CN105143230B (zh) | 2017-06-09 |
| MX2015007939A (es) | 2016-03-11 |
| CU20150066A7 (es) | 2015-11-27 |
| EA201591177A1 (ru) | 2015-11-30 |
| CN105143230A (zh) | 2015-12-09 |
| JP6284546B2 (ja) | 2018-02-28 |
| US20150336986A1 (en) | 2015-11-26 |
| AU2013365739A1 (en) | 2015-07-09 |
| AP2015008539A0 (en) | 2015-06-30 |
| PE20151055A1 (es) | 2015-08-05 |
| TN2015000279A1 (en) | 2016-10-03 |
| EP2935278B1 (en) | 2017-03-15 |
| BR112015014292A2 (pt) | 2017-07-11 |
| PH12015501386A1 (en) | 2015-09-02 |
| US9359381B2 (en) | 2016-06-07 |
| SG11201504594QA (en) | 2015-07-30 |
| CL2015001730A1 (es) | 2015-08-28 |
| TW201429974A (zh) | 2014-08-01 |
| US20140171417A1 (en) | 2014-06-19 |
| WO2014097148A1 (en) | 2014-06-26 |
| UY35211A (es) | 2014-07-31 |
| KR20150097660A (ko) | 2015-08-26 |
| AR094122A1 (es) | 2015-07-08 |
| CA2895660A1 (en) | 2014-06-26 |
| ES2628369T3 (es) | 2017-08-02 |
| EP2935278A1 (en) | 2015-10-28 |
| IL239389A0 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1209741A1 (en) | Tricyclic compounds for inhibiting the cftr channel | |
| IN2015DN00185A (https=) | ||
| WO2014002051A3 (en) | Complement pathway modulators and uses thereof | |
| WO2014002058A3 (en) | Complement pathway modulators and uses thereof | |
| HK1206017A1 (en) | Complement pathway modulators and uses thereof | |
| TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| MY176488A (en) | 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
| MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| PH12013501800A1 (en) | Tricyclic gyrase inhibitors | |
| MX2015007940A (es) | Compuestos tricíclicos como inhibidores de cftr. | |
| MY186598A (en) | Carboxamide derivatives | |
| WO2012140596A8 (en) | Glycoside derivatives and uses thereof | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| PH12015501056A1 (en) | 2-pyridone compound | |
| TN2012000617A1 (en) | 2,3,5-trisubstituted thiophene compounds and uses thereof | |
| PH12013500155A1 (en) | 2,3,5-trisubstituted thiophene compounds and uses thereof | |
| WO2013035997A3 (en) | Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt |